More on QURE
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $48.16 |
|
|||
| Open | $48.88 | ||||
| 52 Wk High | $22.79 | ||||
| 52 Wk Low | $6.63 | ||||
| Day High | $50.08 | ||||
| Day Low | $45.76 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 4,859,912 | ||||
- uniQure reports early data from AMT-260 epilepsy gene therapy trial
- uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
- Form 144 uniQure N.V. Filed by: Kapusta Matthew C
- uniQure BV (QURE) PT Raised to $65 at RBC Capital
- Barclays Upgrades uniQure BV (QURE) to Overweight Following 78% Gain Yesterday
- H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
- uniQure BV (QURE) PT Raised to $70 at Leerink
- Form 144 uniQure N.V. Filed by: Kapusta Matthew C
- Form 4 uniQure N.V. For: Jun 15 Filed by: Balachandran Madhavan
- Form 4 uniQure N.V. For: Jun 15 Filed by: Potts Jeannette
Entities mentioned with QURE
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- Chardan Capital Markets | View Related Stories »
- Show More...
